International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

Pharmacogenetics Committee

PhG Haufroid ViceChair 150x200

Chair

Vincent Haufroid
Brussels, Belgium

contactus273x169

Contact Us
Scientific Committees
Pharmacogenetics Committee

2017 19 PhG Picard Nicolas Vice chair 150x200

Vice-Chair

Nicholas Picard
Limoges, France

Background & Purpose of the Committee

  • To promote the knowledge about clinically relevant DNA testing to optimize drug therapy
  • To enhance the translation of research into clinical practice
  • To encourage discussions on the clinical relevance of specific pharmacogenetics tests, to encourage research into clinically important areas with respect to drug treatment
  • To encourage interaction between pharmacologist and toxicologist to promote “toxicogenetics”

Committee Initiatives for 2016/2017

  • Develop educational materials for PGx
  • Prepare first guideline manuscript
  • Interact/represent IATDMCT in international PGx activities
  • Perfom survey on PGx clinical use among IATDMCT members

Committee Initiatives Completed in 2014/2015

  • Informed members of IATDMCT on current discussions regarding PGx testing, on new potentially interesting pharmacogenetic markers, and the emergence of new technologies.
  • Represented IATDMCT in  IFCC, AACC, EFLM, IUPHAR and ESPT for initiatives on PGx.
  • Advised IATDMCT Rotterdam committee on scientific program regarding PGx

Additional Committee Resources

Coming Soon!
This section will be updated during the 2016 second phase website redesign.